# A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

> **NCT06203210** · PHASE3 · RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 540 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Ifinatamab deruxtecan
- **DRUG:** Topotecan
- **DRUG:** Amrubicin
- **DRUG:** Lurbinectedin

## Key facts

- **NCT ID:** NCT06203210
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-21
- **Primary completion:** 2027-04-30
- **Final completion:** 2029-02-22
- **Target enrollment:** 540 (ESTIMATED)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06203210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06203210, "A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06203210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*